Login to Your Account



Pharma: Other News To Note


Wednesday, November 13, 2013
• Helsinn Group, of Lugano, Switzerland, said it granted Chugai Pharma Marketing Ltd., a wholly owned subsidiary of Chugai Pharmaceutical Co. Ltd., of Tokyo, exclusive commercialization rights to Phase III-stage ghrelin receptor agonist, anamorelin, in Germany, France, Benelux, UK and Ireland.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription